These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 16020962)

  • 21. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-hour paclitaxel in the treatment of non-small cell lung cancer.
    Hainsworth JD; Greco FA
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):98-101. PubMed ID: 9007133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
    Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
    Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin.
    Buccheri G; Ferrigno D;
    Lung Cancer; 2004 Aug; 45(2):227-36. PubMed ID: 15246195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer.
    Gridelli C; Rossi A; Incoronato P; Bruni GS; Scognamiglio F; Ruffolo P; Rinaldi L; Bianco AR
    Cancer Chemother Pharmacol; 1996; 37(6):613-5. PubMed ID: 8612318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma.
    Ceresoli GL; Dell'Oro S; Passoni P; Villa E
    Cancer; 2000 Jul; 89(1):89-96. PubMed ID: 10897005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose.
    Quantin X; Rivière A; Daurès JP; Oliver P; Comte-Bardonnet M; Khial F; Marcillac I; Pujol JL
    Am J Clin Oncol; 2000 Apr; 23(2):192-6. PubMed ID: 10776983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Papadimitriou C; Dafni U; Bafaloukos D; Skarlos D; Moulopoulos LA; Razis E; Kalofonos HP; Aravantinos G; Briassoulis E; Papakostas P; Abela K; Gogas E; Kosmidis P; Pavlidis N; Dimopoulos MA
    J Clin Oncol; 2001 Apr; 19(8):2232-9. PubMed ID: 11304776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study.
    Juan O; Albert A; Ordoño F; Casany R; Carañana V; Campos JM; Alberola V
    Jpn J Clin Oncol; 2002 Nov; 32(11):449-54. PubMed ID: 12499416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
    Pasello G; Carli P; Canova F; Bonanno L; Polo V; Zago G; Urso L; Conte P; Favaretto A
    Anticancer Res; 2015 Apr; 35(4):2183-9. PubMed ID: 25862876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.
    Winegarden JD; Mauer AM; Gajewski TF; Hoffman PC; Krauss S; Rudin CM; Vokes EE
    Lung Cancer; 2003 Feb; 39(2):191-6. PubMed ID: 12581572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
    Fokkema E; de Vries EG; Meijer S; Groen HJ
    Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial.
    Neri B; Cipriani G; Fulignati C; Turrini M; Ponchietti R; Bartoletti R; Della Melina A; Di Cello V; Dominici A; Maleci D; Raugei A; Villari D; Nicita G
    Anticancer Drugs; 2005 Jan; 16(1):63-6. PubMed ID: 15613906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy in the treatment of inoperable non-small cell lung cancer.
    Rutherford RM; Azher T; Gilmartin JJ
    Ir J Med Sci; 2002; 171(4):193-6. PubMed ID: 12647906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group.
    Vermorken JB; Kobierska A; Chevallier B; Zanaboni F; Pawinski A; Bolis G
    Ann Oncol; 2000 Aug; 11(8):1035-40. PubMed ID: 11038042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin.
    Stathopoulos GP; Rigatos S; Malamos NA
    Oncol Rep; 1999; 6(4):797-800. PubMed ID: 10373659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).
    Martoni A; Guaraldi M; Casadio M; Busutti L; Pannuti F
    Ann Oncol; 1992 Dec; 3(10):864-6. PubMed ID: 1337467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.
    Smit EF; Piers DA; Postmus PE
    Eur J Cancer; 1992; 28A(12):1965-7. PubMed ID: 1329882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer.
    Hatzidaki D; Agelaki S; Mavroudis D; Vlachonikolis I; Alegakis A; Georgoulias V;
    Clin Lung Cancer; 2006 Jul; 8(1):49-55. PubMed ID: 16870046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of high-dose epirubicin in advanced non-small cell lung cancer.
    Martoni A; Melotti B; Guaraldi M; Pannuti F
    Eur J Cancer; 1991; 27(10):1231-4. PubMed ID: 1659841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.